Anaphylaxis is rare due to CoronaVac in a population of healthcare workers.
Anaphylaxis
COVID-19
CoronaVac
Local injection site reaction
Systemic skin reactions
Vaccine-associated allergic reactions
Journal
Asia Pacific allergy
ISSN: 2233-8276
Titre abrégé: Asia Pac Allergy
Pays: Netherlands
ID NLM: 101561954
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
12
06
2022
accepted:
13
10
2022
entrez:
1
12
2022
pubmed:
2
12
2022
medline:
2
12
2022
Statut:
epublish
Résumé
CoronaVac, the first coronavirus disease 2019 vaccine administered in our country, was found safe in clinical trials. We aimed to reveal the rate and features of CoronaVac vaccine-associated allergic reactions among vaccinated healthcare workers (HCWs) in real-life. This study was planned as a questionnaire-based study. Participants who reported a postvaccination allergic reaction were interviewed on phone and their medical records were also checked for confirmation. A total of 2,488 HCWs took part in the study and 4,054 postvaccination complete questionnaire-responses were obtained. Twenty-one HCWs (female: male, 17:4) with a mean age of 40.95 ± 10.09 stated that they had an allergic reaction after a total of 23 vaccine injections. Accordingly, the reaction rate was 0.56% among all vaccine doses. The most common reactions were systemic skin reactions (2.7%) consisting of generalized pruritus, diffuse pruritic erythema, urticaria, and maculopapular rash. That was followed by local injection site reaction (0.12%). Anaphylaxis was reported in 4 cases (0.09%) with a mean onset time of 12 ± 6 minutes. One of them had a history of anaphylaxis with 2 drugs, another had venom and food allergy. Three of the subjects had level 2 diagnostic certainty according to the Brighton Collaboration criteria and one had level 3. All anaphylaxis cases were discharged within 24 hours and none of them required intensive care. Our study demonstrated that allergic reactions to CoronaVac were rare and mostly mild. Although anaphylaxis was also rare, the importance of early intervention with close follow-up was once again emphasized.
Sections du résumé
Background
UNASSIGNED
CoronaVac, the first coronavirus disease 2019 vaccine administered in our country, was found safe in clinical trials.
Objective
UNASSIGNED
We aimed to reveal the rate and features of CoronaVac vaccine-associated allergic reactions among vaccinated healthcare workers (HCWs) in real-life.
Methods
UNASSIGNED
This study was planned as a questionnaire-based study. Participants who reported a postvaccination allergic reaction were interviewed on phone and their medical records were also checked for confirmation.
Results
UNASSIGNED
A total of 2,488 HCWs took part in the study and 4,054 postvaccination complete questionnaire-responses were obtained. Twenty-one HCWs (female: male, 17:4) with a mean age of 40.95 ± 10.09 stated that they had an allergic reaction after a total of 23 vaccine injections. Accordingly, the reaction rate was 0.56% among all vaccine doses. The most common reactions were systemic skin reactions (2.7%) consisting of generalized pruritus, diffuse pruritic erythema, urticaria, and maculopapular rash. That was followed by local injection site reaction (0.12%). Anaphylaxis was reported in 4 cases (0.09%) with a mean onset time of 12 ± 6 minutes. One of them had a history of anaphylaxis with 2 drugs, another had venom and food allergy. Three of the subjects had level 2 diagnostic certainty according to the Brighton Collaboration criteria and one had level 3. All anaphylaxis cases were discharged within 24 hours and none of them required intensive care.
Conclusion
UNASSIGNED
Our study demonstrated that allergic reactions to CoronaVac were rare and mostly mild. Although anaphylaxis was also rare, the importance of early intervention with close follow-up was once again emphasized.
Identifiants
pubmed: 36452009
doi: 10.5415/apallergy.2022.12.e35
pmc: PMC9669466
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e35Informations de copyright
Copyright © 2022. Asia Pacific Association of Allergy, Asthma and Clinical Immunology.
Déclaration de conflit d'intérêts
Conflict of Interest: The authors have no financial conflicts of interest.
Références
PLoS One. 2013 Sep 09;8(9):e74445
pubmed: 24040248
Postepy Dermatol Alergol. 2016 Jun;33(3):243-5
pubmed: 27512363
J Med Virol. 2022 Apr;94(4):1442-1449
pubmed: 34783049
Lancet Infect Dis. 2010 May;10(5):338-49
pubmed: 20417416
J Allergy Clin Immunol. 2018 Feb;141(2):463-472
pubmed: 29413255
Lancet Infect Dis. 2021 Jun;21(6):803-812
pubmed: 33548194
Eur J Pediatr. 2019 Jan;178(1):69-75
pubmed: 30269250
Vaccine. 2007 Aug 1;25(31):5675-84
pubmed: 17448577
Lancet Infect Dis. 2021 Feb;21(2):181-192
pubmed: 33217362
Clin Microbiol Infect. 2022 Feb;28(2):202-221
pubmed: 34715347
Przegl Epidemiol. 2015;69(4):731-4, 871-4
pubmed: 27139352
Med Mal Infect. 2020 Feb;50(1):16-21
pubmed: 31611133
Cochrane Database Syst Rev. 2012 Apr 18;(4):CD007596
pubmed: 22513951
Br J Clin Pharmacol. 2019 Dec;85(12):2694-2706
pubmed: 31472022
Lancet. 2021 Jul 17;398(10296):213-222
pubmed: 34246358
J Allergy Clin Immunol Pract. 2019 Sep - Oct;7(7):2232-2238.e3
pubmed: 31035000
J Asthma Allergy. 2021 Oct 07;14:1209-1215
pubmed: 34675550
Allergy Asthma Immunol Res. 2019 Jul;11(4):529-537
pubmed: 31172721
Nature. 2020 Oct;586(7830):516-527
pubmed: 32967006
J Infect Dis. 2014 Jul 15;209 Suppl 3:S114-9
pubmed: 24966191
Nat Rev Immunol. 2021 Feb;21(2):83-100
pubmed: 33353987
J Clin Med. 2021 Jun 15;10(12):
pubmed: 34203769
Allergy. 2004 Apr;59(4):421-7
pubmed: 15005766
Scand J Trauma Resusc Emerg Med. 2017 Nov 22;25(1):111
pubmed: 29166906
Vaccines (Basel). 2021 Mar 05;9(3):
pubmed: 33807579
Nature. 2021 Jan 15;:
pubmed: 33452510
Clin Infect Dis. 2022 Aug 24;75(1):e792-e804
pubmed: 34537835